TRIM66 Overexpression Promotes Glioma Progression and Regulates Glucose Uptake Through cMyc/GLUT3 Signaling

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.2013822237781
   PubMed Web of Science ®Google Scholar
• Krupkova O, Loja T, Redova M, et al. Analysis of nuclear nestin localization in cell lines derived from neurogenic tumors. Tumour Biol. 2011;32(4):631–639. doi:10.1007/s13277-011-0162-921340483
   PubMedGoogle Scholar
• Zadran S, Amighi A, Otiniano E, Wong K, Zadran H. ENTPD5-mediated modulation of ATP results in altered metabolism and decreased survival in gliomablastoma multiforme. Tumour Biol. 2012;33(6):2411–2421. doi:10.1007/s13277-012-0505-122992974
   PubMedGoogle Scholar
• Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42(4):297–311. doi:10.1016/j.tibs.2017.01.00228118948
   PubMed Web of Science ®Google Scholar
• Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792–804. doi:10.1038/nrc313921979307
   PubMed Web of Science ®Google Scholar
• Jaworska AM, Wlodarczyk NA, Mackiewicz A, Czerwinska P. The role of TRIM family proteins in the regulation of cancer stem cell self-renewal. Stem Cells. 2020;38(2):165–173. doi:10.1002/stem.310931664748
   PubMed Web of Science ®Google Scholar
• McAvera RM, Crawford LJ. TIF1 proteins in genome stability and cancer. Cancers. 2020;12(8):2094. doi:10.3390/cancers12082094
   PubMed Web of Science ®Google Scholar
• Fan W, Du F, Liu X. TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3beta-dependent Wnt/beta-catenin signaling. Eur J Pharmacol. 2019;850:109–117. doi:10.1016/j.ejphar.2019.01.05430710548
   PubMed Web of Science ®Google Scholar
• Cao H, Gao R, Chen L, Feng Y. TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway. FEBS Open Bio. 2020;10:515–524. doi:10.1002/2211-5463.12798
   PubMed Web of Science ®Google Scholar
• Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Der Pathologe. 1987;8(3):138–140. German.3303008
   PubMed Web of Science ®Google Scholar
• Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221. doi:10.1186/s13000-014-0221-925432701
   PubMed Web of Science ®Google Scholar
• Annibali D, Whitfield JR, Favuzzi E, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. Nat Commun. 2014;5:4632. doi:10.1038/ncomms563225130259
   PubMed Web of Science ®Google Scholar
• Plummer S, Wallace S, Ball G, et al. A human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Sci Rep. 2019;9(1):1407. doi:10.1038/s41598-018-38130-030723234
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. doi:10.1016/j.gendis.2016.04.00730258889
   PubMed Web of Science ®Google Scholar
• Agnihotri S, Burrell K, Buczkowicz P, et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov. 2014;4(10):1198–1213. doi:10.1158/2159-8290.CD-14-015725100205
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo Y, Yang H, et al. TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. Oncotarget. 2015;6(27):23708–23719. doi:10.18632/oncotarget.429126247633
   PubMedGoogle Scholar
• Ma Y, Dai HY, Zhang F, Zhao D. TRIM66 expression in non-small cell lung cancer: a new predictor of prognosis. Cancer Biomark. 2017;20(3):309–315. doi:10.3233/CBM-17020728946563
   PubMed Web of Science ®Google Scholar
• Dai HY, Ma Y, Da Z, Hou XM. Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer. Pathol Res Pract. 2018;214(8):1130–1135. doi:10.1016/j.prp.2018.06.00829929749
   PubMed Web of Science ®Google Scholar
• He T, Cui J, Wu Y, Sun X, Chen N. Knockdown of TRIM66 inhibits cell proliferation, migration and invasion in colorectal cancer through JAK2/STAT3 pathway. Life Sci. 2019;235:116799. doi:10.1016/j.lfs.2019.11679931472144
   PubMed Web of Science ®Google Scholar
• Fu L, Dong Q, He J, et al. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway. Oncogene. 2017;36(19):2724–2736. doi:10.1038/onc.2016.42527941873
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.116080919460998
   PubMed Web of Science ®Google Scholar
• Xu M, Chen S, Yang W, et al. FGFR4 links glucose metabolism and chemotherapy resistance in breast cancer. Cell Physiol Biochem. 2018;47(1):151–160. doi:10.1159/00048975929763898
   PubMedGoogle Scholar
• Bao Z, Chen K, Krepel S, et al. High glucose promotes human glioblastoma cell growth by increasing the expression and function of chemoattractant and growth factor receptors. Transl Oncol. 2019;12(9):1155–1163. doi:10.1016/j.tranon.2019.04.01631207546
   PubMed Web of Science ®Google Scholar
• Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res. 2006;4(5):319–330. doi:10.1158/1541-7786.MCR-05-006116687487
   PubMed Web of Science ®Google Scholar
• Wang T, Ning K, Sun X, Zhang C, Jin LF, Hua D. Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer. BMC Cancer. 2018;18(1):207. doi:10.1186/s12885-018-4123-129463225
   PubMed Web of Science ®Google Scholar
• Atif F, Yousuf S, Espinosa-Garcia C, Sergeeva E, Stein DG. Progesterone treatment attenuates glycolytic metabolism and induces senescence in glioblastoma. Sci Rep. 2019;9(1):988. doi:10.1038/s41598-018-37399-530700763
   PubMed Web of Science ®Google Scholar
• Miyai M, Kanayama T, Hyodo F, et al. Glucose transporter Glut1 controls diffuse invasion phenotype with perineuronal satellitosis in diffuse glioma microenvironment. Neuro Oncol Adv. 2021;3(1):vdaa150. doi:10.1093/noajnl/vdaa150
   PubMedGoogle Scholar
• Abbadi S, Rodarte JJ, Abutaleb A, et al. Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion. Mol Cancer Res. 2014;12(11):1547–1559. doi:10.1158/1541-7786.MCR-14-0106-T25001192
   PubMed Web of Science ®Google Scholar
• Cho H, Lee YS, Kim J, Chung JY, Kim JH. Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. Cancer Invest. 2013;31(9):607–615. doi:10.3109/07357907.2013.84972224164300
   PubMed Web of Science ®Google Scholar
• Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72(10):2979–2985. doi:10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X8221565
   PubMed Web of Science ®Google Scholar
• Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism. 2016;65(2):124–139. doi:10.1016/j.metabol.2015.10.00726773935
   PubMed Web of Science ®Google Scholar
• Cosset E, Ilmjarv S, Dutoit V, et al. Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. Cancer Cell. 2017;32(6):856–868 e855. doi:10.1016/j.ccell.2017.10.01629198914
   PubMed Web of Science ®Google Scholar
• Zheng C, Yang K, Zhang M, et al. Specific protein 1 depletion attenuates glucose uptake and proliferation of human glioma cells by regulating GLUT3 expression. Oncol Lett. 2016;12(1):125–131. doi:10.3892/ol.2016.459927347112
   PubMed Web of Science ®Google Scholar
• Liu Y, Li YM, Tian RF, et al. The expression and significance of HIF-1alpha and GLUT-3 in glioma. Brain Res. 2009;1304:149–154. doi:10.1016/j.brainres.2009.09.08319782666
   PubMed Web of Science ®Google Scholar
• Kuang R, Jahangiri A, Mascharak S, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017;2(2):e88815. doi:10.1172/jci.insight.8881528138554
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarabi A, Hushmandi K, et al. C-Myc signaling pathway in treatment and prevention of brain tumors. Curr Cancer Drug Targets. 2020;20:104–114. doi:10.2174/156800961966619102310004631657687
   PubMed Web of Science ®Google Scholar
• Shervington A, Cruickshanks N, Wright H, et al. Glioma: what is the role of c-Myc, hsp90 and telomerase? Mol Cell Biochem. 2006;283(1–2):1–9. doi:10.1007/s11010-006-2495-z16444580
   PubMed Web of Science ®Google Scholar
• Wang J, Wang H, Li Z, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008;3(11):e3769. doi:10.1371/journal.pone.000376919020659
   PubMed Web of Science ®Google Scholar
• Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000;275(29):21797–21800. doi:10.1074/jbc.C00002320010823814
   PubMed Web of Science ®Google Scholar